ATE391724T1 - FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF) - Google Patents

FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)

Info

Publication number: ATE391724T1
Authority: AT; Austria
Prior art keywords: ctgf; ßconnective; factorß; fragment; tissue growth
Prior art date: 1998-12-14

Application number

AT99966224T

Other languages

English (en)

Inventor

Gary Grotendorst

Thomas Neff

Original Assignee

Univ Miami

Fibrogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-14

Filing date

1999-12-14

Publication date

2008-04-15

1999-12-14 Application filed by Univ Miami, Fibrogen Inc filed Critical Univ Miami

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391724T1 publication Critical patent/ATE391724T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Oncology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Endocrinology (AREA)

AT99966224T 1998-12-14 1999-12-14 FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF) ATE391724T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11224198P	1998-12-14	1998-12-14
US11224098P	1998-12-14	1998-12-14

Publications (1)

Publication Number	Publication Date
ATE391724T1 true ATE391724T1 (de)	2008-04-15

Family

ID=26809725

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99965256T ATE364617T1 (de)	1998-12-14	1999-12-14	Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon
AT99966224T ATE391724T1 (de)	1998-12-14	1999-12-14	FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT99965256T ATE364617T1 (de)	1998-12-14	1999-12-14	Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon

Country Status (16)

Country	Link
US (3)	US6492129B1 (de)
EP (2)	EP1140964B1 (de)
JP (2)	JP4722290B2 (de)
KR (2)	KR100664625B1 (de)
CN (3)	CN1187370C (de)
AT (2)	ATE364617T1 (de)
AU (3)	AU775391B2 (de)
CA (2)	CA2354422A1 (de)
CY (1)	CY1108860T1 (de)
DE (2)	DE69936315T2 (de)
DK (1)	DK1140969T3 (de)
ES (2)	ES2304811T3 (de)
HK (2)	HK1041268B (de)
MX (1)	MXPA01005949A (de)
PT (1)	PT1140969E (de)
WO (2)	WO2000035936A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996001896A1 (en)	1994-07-12	1996-01-25	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US7026299B2 (en)	1994-07-12	2006-04-11	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US7115390B1 (en) *	1998-12-14	2006-10-03	Fibrogen, Inc.	Connective tissue growth factor fragments and methods and uses thereof
JP4722290B2 (ja) *	1998-12-14	2011-07-13	ユニバーシティーオブマイアミ	結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
AU2001276868A1 (en) *	2000-07-11	2002-01-21	Human Genome Sciences, Inc.	Connective tissue growth factor-2
JP4226471B2 (ja) *	2001-09-18	2009-02-18	ファイブローゲン、インコーポレーテッド	結合組織増殖因子の分析方法
CN1604783A (zh) *	2001-10-26	2005-04-06	里伯药品公司	通过rna干扰治疗纤维化疾病的药物
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
CN1602207A (zh) *	2001-12-11	2005-03-30	法布罗根股份有限公司	抑制眼病理过程的方法
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en) *	2003-06-04	2008-07-29	Fibrogen, Inc.	Connective tissue growth factor antibodies
US20050153395A1 (en) *	2003-09-29	2005-07-14	Children's Hospital Inc.	Unique integrin binding site in connective tissue growth factor (CTGF)
WO2005038013A1 (en)	2003-10-07	2005-04-28	Isis Pharmaceuticals, Inc.	Artisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
GB0326778D0 (en) *	2003-11-18	2003-12-24	Imp College Innovations Ltd	Biological materials and uses thereof
EP1715890B1 (de) *	2004-02-11	2008-07-09	Fibrogen, Inc.	Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
CN1929861B (zh) *	2004-02-11	2010-12-29	法布罗根股份有限公司	Ctgf作为糖尿病肾病的治疗靶点
MXPA06012576A (es)	2004-04-28	2007-01-31	Fibrogen Inc	Tratamientos para cancer pancreatico.
WO2005116194A1 (ja) *	2004-05-25	2005-12-08	Riken	試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (de) *	2005-02-22	2006-08-23	Boehringer Ingelheim International GmbH	Transgenes Tier als Modell für Lungenkrankheiten des Menschen
US8088381B2 (en)	2005-05-05	2012-01-03	Fibrogen, Inc.	Methods of treatment of cardiovascular disease using anti-CTGF agents
KR20080090408A (ko)	2005-11-30	2008-10-08	아보트 러보러터리즈	항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CA2631195C (en)	2005-11-30	2016-04-05	Abbott Laboratories	Monoclonal antibodies against amyloid beta protein and uses thereof
US20100034892A1 (en) *	2006-08-30	2010-02-11	The Trustees Of Columbia University In The City Of New York	Treatment for bone formation disorders by growth factor delivery
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
WO2009061382A2 (en) *	2007-11-02	2009-05-14	Marban Eduardo T	Cardiac stem cell and myocyte secreted paracrine factors and uses thereof
US8946172B2 (en)	2008-08-25	2015-02-03	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010027830A2 (en) *	2008-08-25	2010-03-11	Excaliard Pharmaceuticals, Inc.	Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
EP3081648A1 (de)	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
EP2340309A2 (de)	2008-09-22	2011-07-06	Rxi Pharmaceuticals Corporation	Neutrale nanotransporter
US8771692B2 (en)	2009-07-02	2014-07-08	Fibrogen, Inc.	Methods for treatment of muscular dystrophy
WO2011056234A1 (en)	2009-11-06	2011-05-12	Fibrogen, Inc.	Treatment for radiation-induced disorders
KR101852210B1 (ko)	2010-03-24	2018-04-25	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
KR101249041B1 (ko) *	2010-04-28	2013-03-29	포항공과대학교 산학협력단	결합조직 성장인자를 이용한 약학적 조성물
EP2603524A1 (de)	2010-08-14	2013-06-19	AbbVie Inc.	Amyloid-beta-bindende proteine
US20140134181A1 (en)	2010-11-05	2014-05-15	Kenneth E. Lipson	Treatment Method For Lung Remodeling Diseases
US9102721B2 (en)	2011-01-21	2015-08-11	Fibrogen, Inc.	Therapeutic method
ES2729956T3 (es) *	2011-02-02	2019-11-07	Excaliard Pharmaceuticals Inc	Compuestos antisentido dirigidos al factor de crecimiento de tejido conectivo (ctgf) para su uso en un procedimiento de tratamiento de queloides o cicatrices hipertróficas
EA029290B1 (ru) *	2011-12-22	2018-03-30	Астеллас Фарма Инк.	Новое антитело против ctgf человека
US9480449B2 (en)	2012-05-03	2016-11-01	Fibrogen, Inc.	Methods for treating idiopathic pulmonary fibrosis
US9132171B2 (en)	2012-05-23	2015-09-15	Wisconsin Alumni Research Foundation	Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en)	2014-01-28	2017-04-25	Fibrogen, Inc.	Therapeutic method for pancreatic cancer
JP2018517418A (ja)	2015-06-15	2018-07-05	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	情動障害の診断および治療の方法
CN109402127B (zh) *	2018-09-29	2021-12-10	复旦大学附属眼耳鼻喉科医院	一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) *	2020-04-13	2020-07-17	西南大学	基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US392024A (en) *		1888-10-30		Jjett
US4906742A (en) *	1986-07-31	1990-03-06	Whitehead Institute For Biomedical Research	Encoding antigens of M. Leprae
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5071773A (en) *	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
FR2678283A1 (fr) *	1991-06-25	1992-12-31	Centre Nat Rech Scient	Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) *	1991-08-30	1995-04-18	University Of South Florida	Connective tissue growth factor(CTGF)
US5770209A (en) *	1991-08-30	1998-06-23	University Of South Florida	Acceleration of wound healing using connective tissue growth factor
US5474796A (en) *	1991-09-04	1995-12-12	Protogene Laboratories, Inc.	Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) *	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) *	1992-07-24	1997-01-21	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human VCAM-1 RNA
WO1996001896A1 (en) *	1994-07-12	1996-01-25	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US5789389A (en) *	1995-03-17	1998-08-04	Board Of Trustees Of University Of Illinois	BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en)	1995-06-01	1997-11-18	The University Of Medicine And Dentistry Of New Jersey	Long term maintenance of lymphocytes in vitro
EP0871705A4 (de) *	1995-06-05	2000-01-26	Human Genome Sciences Inc	Menschlicher ccn-ähnlicher wachstumsfaktor
EP0827742A1 (de) *	1996-09-04	1998-03-11	Vrije Universiteit Brussel	Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5876730A (en) *	1997-08-07	1999-03-02	Childrens Hospital Research Foundation	Heparin-binding growth factor (HBGF) polypeptides
EP1043335A4 (de) *	1997-12-25	2005-08-31	Japan Tobacco Inc	Monoklonaler antikörper gegen den bindegewebewachstumsfaktor sowie dessen medizinische verwendungen
CA2321176A1 (en) *	1998-02-20	1999-08-26	Zymogenetics, Inc.	Connective tissue growth factor homologs
US6238921B1 (en) *	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) *	1998-11-06	2002-02-19	Fibrogen, Inc.	Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
JP4722290B2 (ja) *	1998-12-14	2011-07-13	ユニバーシティーオブマイアミ	結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
US7405274B2 (en) *	2003-06-04	2008-07-29	Fibrogen, Inc.	Connective tissue growth factor antibodies

1999
- 1999-12-14 JP JP2000588194A patent/JP4722290B2/ja not_active Expired - Lifetime
- 1999-12-14 KR KR1020017007367A patent/KR100664625B1/ko active IP Right Grant
- 1999-12-14 PT PT99965256T patent/PT1140969E/pt unknown
- 1999-12-14 US US09/461,688 patent/US6492129B1/en not_active Expired - Lifetime
- 1999-12-14 CN CNB998158747A patent/CN1187370C/zh not_active Expired - Lifetime
- 1999-12-14 AU AU21819/00A patent/AU775391B2/en not_active Expired
- 1999-12-14 AT AT99965256T patent/ATE364617T1/de active
- 1999-12-14 EP EP99966224A patent/EP1140964B1/de not_active Expired - Lifetime
- 1999-12-14 AU AU31211/00A patent/AU773278B2/en not_active Expired
- 1999-12-14 CA CA002354422A patent/CA2354422A1/en not_active Abandoned
- 1999-12-14 CN CNB99815850XA patent/CN1170849C/zh not_active Expired - Lifetime
- 1999-12-14 MX MXPA01005949A patent/MXPA01005949A/es unknown
- 1999-12-14 KR KR1020017007410A patent/KR100664626B1/ko active IP Right Grant
- 1999-12-14 WO PCT/US1999/029652 patent/WO2000035936A1/en active IP Right Grant
- 1999-12-14 AT AT99966224T patent/ATE391724T1/de not_active IP Right Cessation
- 1999-12-14 JP JP2000588197A patent/JP4634614B2/ja not_active Expired - Fee Related
- 1999-12-14 DK DK99965256T patent/DK1140969T3/da active
- 1999-12-14 CA CA002354456A patent/CA2354456A1/en not_active Abandoned
- 1999-12-14 WO PCT/US1999/029654 patent/WO2000035939A2/en active IP Right Grant
- 1999-12-14 ES ES99966224T patent/ES2304811T3/es not_active Expired - Lifetime
- 1999-12-14 EP EP99965256A patent/EP1140969B1/de not_active Expired - Lifetime
- 1999-12-14 CN CN2004101024245A patent/CN1660911A/zh active Pending
- 1999-12-14 ES ES99965256T patent/ES2288321T3/es not_active Expired - Lifetime
- 1999-12-14 DE DE69936315T patent/DE69936315T2/de not_active Expired - Lifetime
- 1999-12-14 DE DE69938507T patent/DE69938507T2/de not_active Expired - Lifetime
2002
- 2002-04-09 HK HK02102627.5A patent/HK1041268B/zh not_active IP Right Cessation
- 2002-04-10 HK HK02102721.0A patent/HK1041005B/zh not_active IP Right Cessation
- 2002-12-09 US US10/315,568 patent/US7718177B2/en not_active Expired - Lifetime
2004
- 2004-08-20 AU AU2004205171A patent/AU2004205171B2/en not_active Expired
2007
- 2007-07-31 CY CY20071101018T patent/CY1108860T1/el unknown
2010
- 2010-04-06 US US12/755,367 patent/US20100190838A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2004205171A1 (en)	2004-09-16
WO2000035939A3 (en)	2000-10-12
KR100664625B1 (ko)	2007-01-04
HK1041005A1 (en)	2002-06-28
EP1140964A4 (de)	2003-06-18
CA2354422A1 (en)	2000-06-22
CY1108860T1 (el)	2014-07-02
HK1041005B (zh)	2007-11-09
EP1140964B1 (de)	2008-04-09
CA2354456A1 (en)	2000-06-22
MXPA01005949A (es)	2002-09-18
WO2000035936A1 (en)	2000-06-22
DK1140969T3 (da)	2007-09-17
US20100190838A1 (en)	2010-07-29
JP2002532082A (ja)	2002-10-02
DE69936315D1 (de)	2007-07-26
EP1140969A4 (de)	2003-07-23
KR100664626B1 (ko)	2007-01-04
ES2288321T3 (es)	2008-01-01
HK1041268A1 (en)	2002-07-05
ES2304811T3 (es)	2008-10-16
CN1187370C (zh)	2005-02-02
DE69938507D1 (en)	2008-05-21
CN1170849C (zh)	2004-10-13
AU2181900A (en)	2000-07-03
AU775391B2 (en)	2004-07-29
JP2002532084A (ja)	2002-10-02
EP1140969B1 (de)	2007-06-13
US7718177B2 (en)	2010-05-18
US20030180300A1 (en)	2003-09-25
AU2004205171B2 (en)	2007-08-09
KR20010101207A (ko)	2001-11-14
CN1334820A (zh)	2002-02-06
AU3121100A (en)	2000-07-03
ATE364617T1 (de)	2007-07-15
WO2000035939A2 (en)	2000-06-22
US6492129B1 (en)	2002-12-10
JP4634614B2 (ja)	2011-02-16
DE69938507T2 (de)	2009-06-10
EP1140964A2 (de)	2001-10-10
HK1041268B (zh)	2009-02-27
CN1334819A (zh)	2002-02-06
DE69936315T2 (de)	2008-02-14
PT1140969E (pt)	2007-08-30
CN1660911A (zh)	2005-08-31
EP1140969A1 (de)	2001-10-10
AU773278B2 (en)	2004-05-20
JP4722290B2 (ja)	2011-07-13
KR20010101194A (ko)	2001-11-14

Publication	Publication Date	Title
ATE391724T1 (de)	2008-04-15	FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
DE60042137D1 (de)	2009-06-10	Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DE69839815D1 (de)	2008-09-11	Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ES2165878T3 (es)	2002-04-01	Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
HUP9603484A2 (hu)	1998-05-28	Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
DE69914726D1 (de)	2004-03-18	Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69533176D1 (de)	2004-07-22	Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
ATE319812T1 (de)	2006-03-15	Knochen-vorläufer-zellen: zusammensetzungen und methoden
DE69729125D1 (de)	2004-06-17	Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69631478D1 (de)	2004-03-11	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
EP0832100A4 (de)	1998-09-02	Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
ATE214272T1 (de)	2002-03-15	Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE374618T1 (de)	2007-10-15	Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
MX9709910A (es)	1998-07-31	Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
EA199700241A1 (ru)	1998-02-26	Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE285794T1 (de)	2005-01-15	Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
DE60232733D1 (de)	2009-08-06	Alternativ gesplicter zirkulierender gewebefaktor
DE60118769D1 (de)	2006-05-24	Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
KR960000248A (ko)	1996-01-25	골대사 질환 치료제
ATE311901T1 (de)	2005-12-15	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
MX9709908A (es)	1998-07-31	Compuestos cetoheterociclicos, uso de los mismos y composiciones que los contienen.
UA41708A (uk)	2001-09-17	Спосіб лікування порушень регенерації кісткової тканини
RO117234B1 (ro)	2001-12-28	Fibride colagenice şi procedeu de obţinere

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties